Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 1Active not recruiting 1

Sponsor Class

OTHER 1INDUSTRY 1

Study Type

Observational 1Interventional 1

Sponsor

Cancer Type

Breast 2CNS 1

Conditions

Neoplasms 2Neoplasm Metastasis 2Breast Neoplasms 2Sarcoma 1Recurrence 1Prostatic Neoplasms 1Multiple Myeloma 1Carcinoma, Non-Small-Cell Lung 1Brain Neoplasms 1Alopecia 1

Interventions

Fulvestrant 125Trastuzumab 115Paclitaxel 113Letrozole 108pembrolizumab 79pertuzumab 75palbociclib 75Anastrozole 72Capecitabine 71Cyclophosphamide 69Carboplatin 67abemaciclib 64exemestane 63Tamoxifen 63ribociclib 61trastuzumab deruxtecan 58Surveys and Questionnaires 51Specimen Handling 50Radiotherapy 48Magnetic Resonance Spectroscopy 48Docetaxel 48Blood Specimen Collection 40olaparib 39Standard of Care 37Biopsy 34sacituzumab govitecan 31130-nm albumin-bound paclitaxel 31Exercise 29Doxorubicin 29eribulin 27

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Breast Neoplasms × Immunoconjugates × 1 year × Clear all
NCT04829604 2026-03-09

ARX788 in HER2-positive, Metastatic Breast Cancer Subjects (ACE-Breast-03)

Ambrx, Inc.

Phase 2 Active not recruiting
72 enrolled
Breast

Breast Neoplasms, Neoplasm Metastasis

NCT06504719 2025-09-15

Safety and Efficacy Real-world Data of Trastuzumab Deruxtecan and Sacituzumab Govitecan

Hellenic Cooperative Oncology Group

Completed
312 enrolled
BreastCNS

Brain Neoplasms, Breast Neoplasms, Neoplasm Metastasis

Data powered by HemOnc (CC BY 4.0) Colophon âš¡